ADARx Pharma prices upsized $446.3 million IPO
Why now
Thesis: Biotech IPO window shows selective reopening
Catalyst to watch: Aftermarket trading and follow-on deals
Main risk: Single deal, post-IPO performance unknown
Why it matters
An upsized biotech IPO signals reopening risk appetite for clinical-stage pharma issuance.
Sources
- googlenews · news.google.com · 2026-09-28 10:32 UTC